ResMed Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Virgin Galactic Holdings, Inc. trades at $2.84 (market cap $445.69M). The key difference: ResMed Inc. is far larger — about 71.6× Virgin Galactic Holdings, Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| RMD | SPCE | |
|---|---|---|
Market Cap | $31.89B | $445.69M |
Volume | 618,314 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $277.88 | $7.52 |
52-Week Low | $182.82 | $2.17 |
Typical Hold Time | 51 Days | 69 Days |
Enterprise Value | $31.24B | $409.68M |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Virgin Galactic (SPCE) trades at $2.84, down 5.65% on the day, reflecting ongoing volatility amid a bearish technical signal. The company continues to report significant losses with a net income margin of -23,867.44% (2025 financials), though it has beaten EPS estimates in recent quarters. Cash flow remains negative, but the trend is improving, with management targeting positive quarterly cash flow by 2027. Recent news highlights strong ticket demand but also a delay in commercial Delta flights to February 2027.
The outlook remains high-risk due to persistent losses and cash burn, but long-term potential exists in commercial spaceflight. Investment opportunity hinges on successful execution of the Delta program and achieving profitability targets. Key risks include execution delays, high cash burn, competitive pressures, and stock dilution. Analyst sentiment is mixed, with 29.41% buy ratings, reflecting cautious optimism amid substantial operational challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →